HORIZON THERAPEUTICS IRELAND
BiotechHORIZON THERAPEUTICS IRELAND is a biotechnology company focused on Metabolic, Ophthalmology. Key products include TEPEZZA.
FDA Novel Drug Designations
(2020)See 1 novel approval →
HORIZON THERAPEUTICS IRELAND's Key Drugs
HORIZON THERAPEUTICS IRELAND's core commercial portfolio centers on TEPEZZA, spanning Metabolic and Ophthalmology — its most strategically important drugs approved in the last 15 years.
HORIZON THERAPEUTICS IRELAND's Recent FDA Approvals
New NDA/BLA approvals for HORIZON THERAPEUTICS IRELAND over the last two years — novel drugs only, excluding generics and label supplements.
HORIZON THERAPEUTICS IRELAND's Therapeutic Areas
HORIZON THERAPEUTICS IRELAND's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Ophthalmology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HORIZON THERAPEUTICS IRELAND's Top Competitors
HORIZON THERAPEUTICS IRELAND's closest competitors by therapeutic-area and drug-target overlap include Baxter, OTSUKA ICU MEDCL, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HORIZON THERAPEUTICS IRELAND Pipeline Snapshot
Active clinical trials for HORIZON THERAPEUTICS IRELAND across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TEPEZZA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-01-21
- Latest
- 2026-09-23
- Applications
- 1